Anorexia Clinical Trial
Official title:
Distribution of an Energy Rich Formula at Medication Rounds to Individuals Living in Old Peoples Home - Effects on Energy Intake Compared to Standard Nutritional Treatment
Dietary intake in frail elderly is often lower than estimated needs due to the combined effects of the anorexia of ageing, frailty and the presence of acute and chronic disease. The objectives of the present study are to assess the effects of an oleic acid rich formula fortified with micronutrients on energy intake, vitamin- and mineral status, muscle strength and mobility. The investigators have recently performed a similar study in an acute ward setting without micronutrients.
Malnutrition has been reported to be present in up to 55% of acutely hospitalised elderly
and in one third of people living in assisted accommodation. Frail elderly with poor
appetite are at risk for malnutrition. Rebecca Stratton et al have reviewed effects of oral
nutritional supplements (ONS) in elderly hospital patients and key findings in hospital
trials were that ONS can improve intakes of energy, protein and micronutrients without
substantially reducing food intake which may lead to weight gain or attenuate weight loss.
Calogen extra is a fat emulsion containing 400 kcal/100 ml, based on canola and
sunflower-oil which has a good fat composition. Moreover it contains around 30 % of
recommended micronutrients and 5g protein/100 ml. It has potentially positive effects on
energy intake, fatty acid profile and constipation.
The investigators have recently performed a clinical trial in geriatric patients in an
acute-ward setting to evaluate the effects of a similar fat emulsion, Calogen, without
micronutrients. The investigators could conclude that this fat emulsion based on MUFA and
PUFA distributed three times daily at medication rounds may have positive effects on weight,
appetite and serum lipids. Moreover the approach was well accepted by patients and nurses.
The intervention period was very short (median 8 days) therefore the investigators plan to
perform a study with a similar design, for a longer period of time, in a group of elderly
living in old peoples home.
;
Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT01501396 -
Megestrol Acetate With or Without Mirtazapine in Treating Cancer Patients With Weight Loss or Loss of Appetite
|
Phase 2 | |
Withdrawn |
NCT02793102 -
Sensory Workshops and Anorexia Nervosa
|
N/A | |
Active, not recruiting |
NCT01206335 -
Open Label Study With OHR/AVR118 in Advanced Cancer Patients With Anorexia-Cachexia
|
Phase 2 | |
Completed |
NCT02524301 -
Evaluation of Brain Opioid Receptor Activity in Anorexia Nervosa : a PET [11C]Diprenorphine Study
|
N/A | |
Active, not recruiting |
NCT00488072 -
Effects of Mirtazapine on Appetite in Advanced Cancer Patients
|
Phase 2 | |
Withdrawn |
NCT05039385 -
Exercise Program in Patients With Anorexia Nervosa (ESATRAL)
|
N/A | |
Completed |
NCT03097874 -
Adaptive Treatment for Adolescent Anorexia Nervosa
|
N/A | |
Completed |
NCT00031785 -
Megestrol in Treating Patients Who Are Undergoing Radiation Therapy for Lung Cancer
|
Phase 3 | |
Terminated |
NCT00558558 -
Haelan and Nutrition in Cancer Patients
|
Phase 2 | |
Terminated |
NCT00535015 -
Safety and Efficacy Study of Betamarc to Treat Loss of Weight and Appetite in Non-Small Cell Lung Cancer
|
Phase 2 | |
Completed |
NCT00040885 -
Docetaxel With or Without Infliximab in Treating Weight Loss, Loss of Appetite, and Fatigue in Patients With Unresectable Non-Small Cell Lung Cancer (Infliximab Treatment Discontinued Effective 10/05/05)
|
Phase 3 | |
Completed |
NCT00006799 -
Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck Cancer
|
Phase 3 | |
Active, not recruiting |
NCT03637816 -
Anamorelin Hydrochloride in Reducing Anorexia in Patients With Advanced Non-small Cell Lung Cancer
|
Phase 2/Phase 3 | |
Completed |
NCT04007900 -
Positive Affect Treatment (PAT) to Target Reward Mechanisms in Anorexia Nervosa
|
N/A | |
Completed |
NCT00735540 -
Clinical Diagnosis of Teenagers Admitted to Pediatric Departments
|
N/A | |
Completed |
NCT00046904 -
Etanercept in Treating Cancer-Related Cachexia and Anorexia in Patients With Advanced Cancer
|
Phase 3 | |
Completed |
NCT04803305 -
Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and Anorexia
|
Phase 1 | |
Completed |
NCT05708404 -
Outpatient Treatment of Severe and Enduring Anorexia Nervosa
|
||
Completed |
NCT03283488 -
Comparison Between Mirtazapine and Megestrol for the Control of Anorexia-cachexia in Cancer Patients in Palliative Care.
|
Phase 2 | |
Recruiting |
NCT05503147 -
Sativex® and Gentamicin for Optimized Pharmagological Treatment in Older Patients (CanPan)
|
Phase 1 |